Medifast Stock Price, News & Analysis (NYSE:MED) $69.72 +1.41 (+2.06%) (As of 12/4/2023 ET) Add Compare Share Share Today's Range$67.77▼$70.0050-Day Range$62.12▼$76.8752-Week Range$61.94▼$131.42Volume161,423 shsAverage Volume193,920 shsMarket Capitalization$759.25 millionP/E Ratio6.36Dividend Yield9.47%Price Target$81.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Medifast MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside16.2% Upside$81.00 Price TargetShort InterestBearish15.72% of Float Sold ShortDividend StrengthModerateBased on Four FactorsSustainability-3.90Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$414,632 Sold Last QuarterProj. Earnings Growth-17.67%From $9.34 to $7.69 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.89 out of 5 starsConsumer Staples Sector90th out of 134 stocksMiscellaneous Food Preparations & Kindred Products Industry3rd out of 4 stocks 2.0 Analyst's Opinion Consensus RatingMedifast has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $81.00, Medifast has a forecasted upside of 16.2% from its current price of $69.72.Amount of Analyst CoverageMedifast has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted15.72% of the float of Medifast has been sold short.Short Interest Ratio / Days to CoverMedifast has a short interest ratio ("days to cover") of 9.9.Change versus previous monthShort interest in Medifast has recently decreased by 2.89%, indicating that investor sentiment is improving. Previous Next 2.5 Dividend Strength Dividend LeadershipMedifast is a leading dividend payer. It pays a dividend yield of 9.66%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthMedifast has only been increasing its dividend for 3 years.Dividend CoverageThe dividend payout ratio of Medifast is 60.16%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on EPS estimates, Medifast will have a dividend payout ratio of 85.83% in the coming year. This indicates that Medifast may not be able to sustain their current dividend. Previous Next 2.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMedifast has received a 0.00% net impact score from Upright. The largest negative impact of Medifast in category "GHG emissions" seems to be driven mostly by its "Meal replacement soups", "Meal replacement bars", "Meal replacement drinks", and "Protein bars" products. See details.Environmental SustainabilityThe Environmental Impact score for Medifast is -3.90. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Medifast this week, compared to 3 articles on an average week.Search Interest33 people have searched for MED on MarketBeat in the last 30 days. This is an increase of 136% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Medifast to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medifast insiders have sold 3,930.25% more of their company's stock than they have bought. Specifically, they have bought $10,288.00 in company stock and sold $414,632.00 in company stock.Percentage Held by InsidersOnly 2.06% of the stock of Medifast is held by insiders.Percentage Held by Institutions87.83% of the stock of Medifast is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Medifast are expected to decrease by -17.67% in the coming year, from $9.34 to $7.69 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medifast is 6.36, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 118.85.Price to Earnings Ratio vs. SectorThe P/E ratio of Medifast is 6.36, which means that it is trading at a less expensive P/E ratio than the Consumer Staples sector average P/E ratio of about 19.22.Price to Book Value per Share RatioMedifast has a P/B Ratio of 4.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Medifast Stock (NYSE:MED)Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. The company offers bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serves, shakes, smoothies, soft bakes, and soups under the OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home brands. It markets its products through point-of-sale transactions over ecommerce platform. The company was founded in 1980 and is based in Baltimore, Maryland.Read More MED Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MED Stock News HeadlinesNovember 30, 2023 | sg.finance.yahoo.comMedifast, Inc. (MED) interactive stock chart – Yahoo FinanceNovember 26, 2023 | msn.comThe Truth About the Optavia Diet, According to NutritionistsDecember 5, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 25, 2023 | americanbankingnews.comQ4 2023 EPS Estimates for Medifast, Inc. Cut by Zacks Research (NYSE:MED)November 24, 2023 | finance.yahoo.comMedifast (MED) Poised on OPTAVIA ACTIVE Line Amid Cost WoesNovember 24, 2023 | seekingalpha.comMedifast: Good On Paper, But A Slowdown In Sales Is Very WorrisomeNovember 15, 2023 | insidermonkey.com5 Best High-Dividend Stocks to Buy NowNovember 12, 2023 | benzinga.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Medifast, Inc. (NYSE: MED) and Encourages Investors to Contact the FirmDecember 5, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 9, 2023 | seekingalpha.comMedifast: Unveiling A Challenge Beyond Weight Loss DrugsNovember 7, 2023 | finance.yahoo.comQ3 2023 Medifast Inc Earnings CallNovember 7, 2023 | msn.comClose Out: Medifast (MED), November 7, 2023November 7, 2023 | finance.yahoo.comMedifast (MED) Q3 Earnings Top Estimates, Revenues Decline Y/YNovember 7, 2023 | insidermonkey.comMedifast, Inc. (NYSE:MED) Q3 2023 Earnings Call TranscriptNovember 6, 2023 | sfgate.comMedifast: Q3 Earnings SnapshotNovember 6, 2023 | msn.comMedifast GAAP EPS of $2.12, revenue of $235.9MNovember 6, 2023 | finance.yahoo.comMedifast Announces Third Quarter 2023 Financial ResultsNovember 6, 2023 | finance.yahoo.comMedifast Inc (MED) Reports Q3 2023 Earnings: Revenue Down 39.6%, Net Income at $23.1 MillionNovember 6, 2023 | seekingalpha.comMedifast, Inc. 2023 Q3 - Results - Earnings Call PresentationNovember 6, 2023 | finance.yahoo.comMedifast (NYSE:MED) shareholders have endured a 50% loss from investing in the stock three years agoNovember 3, 2023 | benzinga.comPreview: Medifast's EarningsOctober 25, 2023 | finance.yahoo.comMedifast (MED) Poised on Expansion Initiatives Amid Cost WoesOctober 23, 2023 | finance.yahoo.comMedifast to Announce Financial Results for the Third Quarter Ended September 30, 2023October 19, 2023 | finance.yahoo.comMedifast (MED) Targets New Customer SegmentsOctober 13, 2023 | msn.comStephens & Co. Initiates Coverage of Medifast (MED) with Equal-Weight RecommendationOctober 9, 2023 | seekingalpha.comMedifast: The Race To Weight-Loss Drugs Not Lost YetOctober 5, 2023 | finance.yahoo.comMedifast Named as One of the "Best Companies To Work For" by U.S. News & World ReportSee More Headlines Receive MED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medifast and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Ex-Dividend for 11/7 Dividend9/18/2023Last Earnings11/06/2023Dividend Payable11/07/2023Today12/05/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/20/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Miscellaneous food preparations & kindred products Sub-IndustryPersonal Products SectorConsumer Staples Current SymbolNYSE:MED CUSIP58470H10 CIK910329 Webwww.medifast1.com Phone(410) 581-8042Fax410-581-8070Employees874Year FoundedN/APrice Target and Rating Average Stock Price Target$81.00 High Stock Price Target$82.00 Low Stock Price Target$80.00 Potential Upside/Downside+16.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$10.97 Trailing P/E Ratio6.36 Forward P/E Ratio7.46 P/E GrowthN/ANet Income$143.57 million Net Margins9.84% Pretax Margin12.43% Return on Equity76.08% Return on Assets41.99% Debt Debt-to-Equity Ratio0.09 Current Ratio2.04 Quick Ratio1.51 Sales & Book Value Annual Sales$1.60 billion Price / Sales0.47 Cash Flow$16.29 per share Price / Cash Flow4.28 Book Value$14.19 per share Price / Book4.91Miscellaneous Outstanding Shares10,890,000Free Float10,669,000Market Cap$759.25 million OptionableOptionable Beta1.23 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Daniel R. Chard (Age 58)Executive Chairman & CEO Comp: $1.94MMr. James P. Maloney CPA (Age 55)Chief Financial Officer Comp: $823.91kMr. Anthony E. Tyree (Age 58)Chief Business Operations Officer Comp: $655.86kMr. Jason L. Groves Esq. (Age 52)Executive VP, General Counsel & Corporate Secretary Comp: $669.51kMr. Nicholas M. Johnson (Age 43)Chief Field Operations Officer Comp: $696.4kMr. Jonathan Barrett MacKenzie (Age 51)VP of Finance & Chief Accounting Officer Mr. Steven ZenkerVice President of Investor RelationsMs. Claudia C. Greninger (Age 50)Chief Human Resources Officer More ExecutivesKey CompetitorsUtz BrandsNYSE:UTZB&G FoodsNYSE:BGSBioceres Crop SolutionsNASDAQ:BIOXLavoroNASDAQ:LVROForafric GlobalNASDAQ:AFRIView All CompetitorsInsiders & InstitutionsAmerican Century Companies Inc.Bought 49,605 shares on 11/30/2023Ownership: 0.595%Deutsche Bank AGBought 686 shares on 11/24/2023Ownership: 0.365%Public Sector Pension Investment BoardSold 5,865 shares on 11/22/2023Ownership: 0.124%Walleye Trading LLCBought 2,200 shares on 11/21/2023Ownership: 0.000%Comerica BankBought 5,059 shares on 11/21/2023Ownership: 0.046%View All Insider TransactionsView All Institutional Transactions MED Stock Analysis - Frequently Asked Questions Should I buy or sell Medifast stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MED, but not buy additional shares or sell existing shares. View MED analyst ratings or view top-rated stocks. What is Medifast's stock price target for 2024? 2 Wall Street research analysts have issued 1 year price targets for Medifast's stock. Their MED share price targets range from $80.00 to $82.00. On average, they predict the company's share price to reach $81.00 in the next year. This suggests a possible upside of 16.2% from the stock's current price. View analysts price targets for MED or view top-rated stocks among Wall Street analysts. How have MED shares performed in 2023? Medifast's stock was trading at $115.35 at the start of the year. Since then, MED stock has decreased by 39.6% and is now trading at $69.72. View the best growth stocks for 2023 here. When is Medifast's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 20th 2024. View our MED earnings forecast. How were Medifast's earnings last quarter? Medifast, Inc. (NYSE:MED) posted its quarterly earnings results on Monday, November, 6th. The specialty retailer reported $2.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.02 by $1.10. The specialty retailer had revenue of $235.87 million for the quarter, compared to the consensus estimate of $232.10 million. Medifast had a net margin of 9.84% and a trailing twelve-month return on equity of 76.08%. The firm's revenue for the quarter was down 39.6% compared to the same quarter last year. During the same quarter last year, the business posted $3.32 earnings per share. How often does Medifast pay dividends? What is the dividend yield for Medifast? Medifast announced a quarterly dividend on Thursday, September 7th. Investors of record on Tuesday, September 19th will be given a dividend of $1.65 per share on Tuesday, November 7th. This represents a $6.60 annualized dividend and a yield of 9.47%. The ex-dividend date is Monday, September 18th. Read our dividend analysis for MED. Is Medifast a good dividend stock? Medifast (NYSE:MED) pays an annual dividend of $6.60 per share and currently has a dividend yield of 9.66%. MED has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The company has been increasing its dividend for 3 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 60.16%. This payout ratio is at a healthy, sustainable level, below 75%. Based on EPS estimates, MED will have a dividend payout ratio of 85.83% in the coming year. This indicates that the company may not be able to sustain their current dividend. Read our dividend analysis for MED. What ETFs hold Medifast's stock? ETFs with the largest weight of Medifast (NYSE:MED) stock in their portfolio include Invesco S&P SmallCap Consumer Staples ETF (PSCC), First Trust SMID Cap Rising Dividend Achievers ETF (SDVY), Roundhill Acquirers Deep Value ETF (DEEP), Pacer US Small Cap Cash Cows 100 ETF (CALF), Invesco S&P SmallCap Quality ETF (XSHQ), WisdomTree U.S. SmallCap Quality Dividend Growth Fund (DGRS), Royce Quant Small-Cap Quality Value ETF (SQLV) and Global X Health & Wellness ETF (BFIT). What guidance has Medifast issued on next quarter's earnings? Medifast issued an update on its FY23 earnings guidance on Monday, November, 6th. The company provided earnings per share (EPS) guidance of $8.65-$9.55 for the period, compared to the consensus earnings per share estimate of $8.53. The company issued revenue guidance of $1.05-$1.07 billion, compared to the consensus revenue estimate of $1.09 billion. What is Daniel Chard's approval rating as Medifast's CEO? 44 employees have rated Medifast Chief Executive Officer Daniel Chard on Glassdoor.com. Daniel Chard has an approval rating of 93% among the company's employees. This puts Daniel Chard in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Medifast own? Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Home Depot (HD), Boeing (BA), Johnson & Johnson (JNJ), Intel (INTC), Cisco Systems (CSCO), AT&T (T) and Exxon Mobil (XOM). Who are Medifast's major shareholders? Medifast's stock is owned by many different institutional and retail investors. Top institutional investors include Bank of New York Mellon Corp (1.78%), Charles Schwab Investment Management Inc. (1.53%), JPMorgan Chase & Co. (1.40%), Jacobs Levy Equity Management Inc. (1.19%), Northern Trust Corp (1.16%) and AQR Capital Management LLC (1.12%). Insiders that own company stock include Andrea B Thomas, Constance J Hallquist, Constance J Hallquist, Daniel R Chard, Jeffrey J Brown, Jeffrey J Brown, Kevin G Byrnes and Scott Schlackman. View institutional ownership trends. How do I buy shares of Medifast? Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NYSE:MED) was last updated on 12/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medifast, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.